GlassScriptPhysician profile
Jose Angel Bufill
NPI 1558365031
$2,643.41
in general payments reported to CMS, 2019-2025
38 companies · $1,115 in 2025
The $1,115 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $102 · 2021: $132 · 2022: $280 · 2023: $234 · 2024: $302 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.86 |
| Education | $136.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $302.41 | 2020-2025 | Jakafi |
| Janssen Biotech, INC. | $222.62 | 2019-2025 | Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals LP | $218.61 | 2022-2025 | Imfinzi, Lynparza, Onglyza |
| Genentech USA, INC. | $200.19 | 2019-2024 | Perjeta, Kadcyla, Phesgo |
| Novartis Pharmaceuticals Corporation | $177.40 | 2023-2025 | |
| Amgen INC. | $140.36 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $137.20 | 2025 | Opdivo |
| Pfizer INC. | $134.96 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.02 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $103.97 | 2022-2025 | Libtayo |
| Daiichi Sankyo INC. | $75.50 | 2022-2025 | Enhertu, Datroway |
| Genzyme Corporation | $71.13 | 2022-2025 | |
| Astellas Pharma US INC | $58.58 | 2023-2025 | Xospata, Vyloy, Padcev |
| Gilead Sciences, INC. | $54.44 | 2021-2025 | Trodelvy |
| Emd Serono, INC. | $46.34 | 2023-2025 | Bavencio |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Bufill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.